You are here: Industry Insights > Dynavax

News List

Medigen Vaccine Biologics Announces Launch of Its COVID-19 Vaccine MVC-COV1901 Adjuvanted with Dynavax's CpG 1018 Adjuvant prnewswire
August 24, 2021
Medigen Vaccine Biologics Corporation and Dynavax Technologies Corporation today announced the rollout of its COVID-19 vaccine, MVC-COV1901. Approximately 600,000 people are anticipated to receive the Medigen vaccine this week.
Dynavax and Biological E Announce Commercial Supply Agreement of Dynavax's CpG 1018 Adjuvant for Biological E's COVID-19 Vaccine Candidate prnewswire
July 07, 2021
Dynavax Technologies Corporation today announced the execution of a commercial supply agreement of Dynavax's CpG 1018TM advanced adjuvant, for use in BE's subunit COVID-19 vaccine candidate, CORBEVAX™.
Clover and Dynavax Announce Commercial Supply Agreement of Dynavax's CpG 1018 Adjuvant for Clover's COVID-19 Vaccine Candidate prnasia
June 30, 2021
Clover and Dynavax today announced the execution of a commercial supply agreement of Dynavax's CpG 1018TM advanced adjuvant, for use in Clover's protein-based COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum).
Biological E. to begin Phase III trial of COVID-19 vaccine expresspharma
May 10, 2021
Biological E. will soon start Phase III trials of its COVID-19 vaccine and plans to produce 75 million to 80 million doses a month from August, its managing director told Reuters.
First Participants Dosed in Adjuvanted S-Trimer COVID-19 Vaccine Candidate Trial americanpharmaceuticalreview
April 01, 2021
Clover Biopharmaceuticals and Dynavax Technologies announced the first participants have been dosed in Clover's SPECTRA trial (Study Evaluating Protective-Efficacy and Safety of Clover's Trimeric Recombinant Protein-based and Adjuvanted COVID-19 ...
Clover Biopharmaceuticals and Dynavax Announce First Participants Dosed in SPECTRA, a Global Phase 2/3 Clinical Trial for Adjuvanted S-Trimer COVID-19 Vaccine Candidate prnewswire
March 25, 2021
Clover Biopharmaceuticals, a global clinical-stage biotechnology company developing transformative biologics such as vaccines and therapeutics for the world's most debilitating diseases, and Dynavax Technologies Corporation, a biopharmaceutical ...
Dynavax secures EC marketing authorisation for hepatitis B vaccine pharmaceutical-business-review
February 25, 2021
Biopharmaceutical company Dynavax Technologies (DVAX) has secured marketing authorisation from the European Commission (EC) for Heplisav B, a two-dose adult hepatitis B adjuvanted vaccine.
Clover Biopharmaceuticals Announces Publication of Phase 1 Clinical Trial Data for its Adjuvanted COVID-19 Vaccine Candidates in The Lancet prnasia
February 01, 2021
Clover Biopharmaceuticals today announced that the data from its Phase 1 clinical trial evaluating the safety and immunogenicity of its protein-based adjuvanted S-Trimer COVID-19 vaccine candidates was published in the peer-reviewed journal, The Lancet.
First Participant Dosed in COVID-19 Vaccine Trial in Taiwan, China Region americanpharmaceuticalreview
January 29, 2021
Medigen Vaccine Biologics (MVC) and Dynavax Technologies announced the first participant has been dosed in the Phase 2 clinical trial evaluating MVC's COVID-19 vaccine candidate, MVC-COV1901.
European CHMP adopts positive opinion for Dynavax’s HEPLISAV-B vaccine for Hepatitis B pharmaceutical-business-review
December 15, 2020
Dynavax Technologies announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion on the company's Marketing Authorization Application, recommending the granting of marketing ...

Previous page 1 2 Next page